United Therapeutics downgraded by Wells Fargo
$UTHR
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $414.00 | Underweight | Wells Fargo |
| 9/26/2025 | $569.00 | Outperform | RBC Capital Mkts |
| 6/2/2025 | $405.00 | Overweight | Cantor Fitzgerald |
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: "Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital,
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 30 days. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences. Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 10, 2025, from 9:30 a.m. to 10:05 a.m., Eastern Standard Time. James Edgemond, Chief Financial Officer and Treasurer, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, from 12:00 p.m. to 12:25 p.m., Greenwich Mean Time. The sessions can be acce
Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00
RBC Capital Mkts initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $569.00
Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)